Investing in Vaccines: No Venture Wave Despite Government's Big Flu Bucks
This article was originally published in Start Up
Executive Summary
H1N1 concerns mean influenza companies are red hot--but investment in the space over the past five years tells another story.
You may also be interested in...
AAVLife: Another Gene Therapy Effort To Treat Friedreich's Ataxia
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.
With AAVLife Debut, Another Gene Therapy Effort To Treat Friedreich's Ataxia
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.
The Longest Round: NovImmune’s Eight-Year Series B
Several biotechs have kept a private financing round open for several years and extended beyond $100 million, but Swiss antibody firm NovImmune is taking the concept farther than anyone.